Surrozen, Inc. (SRZN)
19.70
-0.98
(-4.71%)
USD |
NASDAQ |
Sep 09, 15:07
Surrozen Debt to Equity Ratio : -0.0289 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0289 |
| March 31, 2026 | -0.0244 |
| December 31, 2025 | -0.0354 |
| September 30, 2025 | -0.3012 |
| June 30, 2025 | 0.1595 |
| March 31, 2025 | 1.404 |
| December 31, 2024 | -0.3961 |
| September 30, 2024 | 0.2695 |
| June 30, 2024 | 0.3573 |
| March 31, 2024 | 0.0924 |
| December 31, 2023 | 0.0891 |
| September 30, 2023 | 0.087 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0822 |
| March 31, 2023 | 0.0805 |
| December 31, 2022 | 0.0737 |
| September 30, 2022 | 0.0789 |
| June 30, 2022 | 0.0738 |
| March 31, 2022 | 0.0703 |
| December 31, 2021 | 0.071 |
| September 30, 2021 | 0.0668 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.2029 |
| September 30, 2020 | 0.03 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 115.61M |
| Total Liabilities (Quarterly) | 334.27M |
| Shareholders Equity (Quarterly) | -218.66M |
| Current Ratio | 12.14 |
| Net Debt Paydown Yield | 0.11% |